Autonomic modulation by SGLT2i or DPP4i in patients with diabetes favors cardiovascular outcomes as revealed by skin sympathetic nerve activity

JJ Chen, C Lin, MT Lo, LY Lin, HC Chang… - Frontiers in …, 2024 - frontiersin.org
Background Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4
inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes …

as revealed by skin sympathetic

C Lin, MT Lo, LY Lin, HC Chang… - … disease: new therapeutic …, 2024 - books.google.com
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and dipeptidyl peptidase-4
inhibitors (DPP4i) are important second-line treatments for patients with type 2 diabetes …